[{"address1": "6-8, Doshomachi 2-chome", "address2": "Chuo-ku", "city": "Osaka", "zip": "541-0045", "country": "Japan", "phone": "81 6 6203 5321", "fax": "81 6 6202 6028", "website": "https://www.sumitomo-pharma.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. It has partnerships with Keio University; RIKEN; Kyoto University; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.", "fullTimeEmployees": 4980, "companyOfficers": [{"maxAge": 1, "name": "Mr. Toru  Kimura Ph.D.", "age": 63, "title": "Representative Director, President & CEO", "yearBorn": 1960, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Motoyuki  Sakai", "age": 62, "title": "Representative Director and Executive VP of Corporate Planning, Corp. Governance, HR & Accounting", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Hiroyuki  Baba", "age": 64, "title": "Mngg Exec. Officer of Global Data Design, Lgl Affairs. IP, IT Mgt, & Frontier Bus. Off.", "yearBorn": 1959, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Naoki  Noguchi", "title": "Executive Officer of Corporate Governance & Communications, VP and Head of Corporate Communications", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Yoshiharu  Ikeda Ph.D.", "age": 65, "title": "Managing Executive Officer of Drug Research Division, Head of Japan Business Unit & Director", "yearBorn": 1958, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Koichi  Kozuki", "title": "E.O. of R. Aff., Med. Sci., C.R.C. & Q.A., Sr. VP, Hd of C.R.C. & Q.A. Div and Dp. Hd of Japan Bus.", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shigeyuki  Nishinaka Ph.D.", "age": 59, "title": "Managing Executive Office, VP and Head of Business Development & Management", "yearBorn": 1964, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Isao  Shimizu", "title": "Executive Officer, Senior VP, Head of Drug Research Division & Senior Executive Research Director", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kenji  Ueno", "title": "Executive Officer, Senior VP and Head of Technology Research & Development Division", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Hideyuki  Harada", "title": "Managing Exe. Officer of Tech. R&D Div., Manufacturing Div. and Dep. Head of Japan Bus. Unit", "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 1, "boardRisk": 3, "compensationRisk": 1, "shareHolderRightsRisk": 3, "overallRisk": 2, "governanceEpochDate": 1725148800, "maxAge": 86400, "priceHint": 4, "open": 2.35, "dayLow": 1.99, "dayHigh": 2.35, "regularMarketOpen": 2.35, "regularMarketDayLow": 1.99, "regularMarketDayHigh": 2.35, "beta": 0.614, "volume": 200, "regularMarketVolume": 200, "bid": 4.17, "ask": 3.1, "marketCap": 1592163200, "fiftyTwoWeekLow": 1.99, "fiftyTwoWeekHigh": 3.29, "priceToSalesTrailing12Months": 0.0048313695, "fiftyDayAverage": 1.99, "twoHundredDayAverage": 2.543775, "trailingAnnualDividendYield": "NaN", "currency": "USD", "enterpriseValue": 312535613440, "profitMargins": -0.78946996, "floatShares": 169555614, "sharesOutstanding": 397289984, "bookValue": 404.885, "priceToBook": 0.0049149757, "lastFiscalYearEnd": 1711843200, "nextFiscalYearEnd": 1743379200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -260166991872, "trailingEps": -4.44, "enterpriseToRevenue": 0.948, "enterpriseToEbitda": -1.152, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "SMDPY", "underlyingSymbol": "SMDPY", "shortName": "SUMITOMO PHARMA CO LTD UNSP ADR", "longName": "Sumitomo Pharma Co., Ltd.", "firstTradeDateEpochUtc": 1668781800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "397c7c09-819e-3b13-992f-3c2777ed910a", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.99, "recommendationKey": "none", "totalCash": 78398996480, "totalCashPerShare": 197.334, "ebitda": -271217000448, "totalDebt": 390072008704, "quickRatio": 0.339, "currentRatio": 0.654, "totalRevenue": 329546989568, "debtToEquity": 242.388, "revenuePerShare": 829.485, "returnOnAssets": -0.19075, "returnOnEquity": -0.90018, "freeCashflow": -190179000320, "operatingCashflow": -136785002496, "revenueGrowth": 0.198, "grossMargins": 0.60219, "ebitdaMargins": -0.823, "operatingMargins": -0.03424, "financialCurrency": "JPY", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]